Management ChangeJun 9, 2026, 05:16 PM
PTC Therapeutics Director Alethia Young Resigns, Becomes Advisor
AI Summary
PTC Therapeutics, Inc. announced that Alethia Young resigned from its Board of Directors, effective June 8, 2026. Ms. Young cited the need to focus on other work commitments as the reason for her departure, clarifying there were no disagreements with the company. She will continue to serve as an advisor to PTC Therapeutics under a consulting agreement, receiving a monthly fee of $4,166.67 for a term extending through June 8, 2027.
Key Highlights
- Alethia Young resigned from PTC Therapeutics' Board of Directors, effective June 8, 2026.
- Her decision was based on commitments to other work activities, not disagreements with the company.
- Ms. Young will remain an advisor to the company through a consulting agreement.
- The consulting agreement is effective June 8, 2026, and continues through June 8, 2027.
- She will receive a monthly consulting fee of $4,166.67.
Price Impact
More from PTCT